Filing Flows › Pure Bioscience (PURE) › Q3 FY26 › vs Q3 FY25
Pure Bioscience (PURE) Q3 FY26 vs Q3 FY25 (year over year)
Pure Bioscience's revenue rose $17K (+3%) from $489K in Q3 FY25 to $506K in Q3 FY26. The biggest changes: SILVERION +$393K (20×); PURE Hard Surface −$376K (-80%).
Pure Bioscience, Q3 FY26: revenue $506K (+4% year over year), operating margin -102.4%, net loss $624K, operating cash flow −$468K. The chart draws each line against Q3 FY25, the increases inside each band.
Every line
| Line | Q3 FY26 | Q3 FY25 | Change | % |
|---|---|---|---|---|
| SILVERION | $414K | $21K | $393K | 20× |
| PURE Hard Surface | $92K | $468K | −$376K | -80% |
| Revenue | $506K | $489K | $17K | +3% |
| Net loss | $624K | $580K | $44K | +8% |
| Costs & expenses | $1.1M | $1.1M | $57K | +5% |
| Operating costs | $1.0M | $1.1M | −$49K | -5% |
| Interest & other, net | $106K | −$4K | $110K | — |
| Cost of revenue | $237K | $206K | $31K | +15% |
| Research & development | $79K | $91K | −$12K | -13% |
| SG&A | $708K | $776K | −$68K | -9% |
| Operating cash sources | $624K | $580K | $44K | +8% |
| Share-based compensation | $55K | $33K | $22K | +67% |
| Working capital & other | $101K | $35K | $66K | +189% |
| Cash used in operations | $468K | $512K | −$44K | -9% |
| Net loss absorbed | $624K | $580K | $44K | +8% |
Questions
How much did Pure Bioscience's revenue grow year over year in Q3 FY26?
Pure Bioscience's revenue rose $17K (+3%) from $489K in Q3 FY25 to $506K in Q3 FY26.
What drove Pure Bioscience's revenue change in Q3 FY26?
SILVERION +$393K (20×); PURE Hard Surface −$376K (-80%).